Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An observational study to collect real world data on Chronic inflammatory demyelinating polyneuropathy patients treated with IVIg (Gamunex ® 10%, Grifols) and to assess safety, tolerability, fatigue and depression.

Trial Profile

An observational study to collect real world data on Chronic inflammatory demyelinating polyneuropathy patients treated with IVIg (Gamunex ® 10%, Grifols) and to assess safety, tolerability, fatigue and depression.

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Jul 2018

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Chronic inflammatory demyelinating polyradiculoneuropathy
  • Focus Adverse reactions
  • Acronyms GAMEDIS-2
  • Most Recent Events

    • 29 Jul 2018 New trial record
    • 19 Jun 2018 Results presented at the 4th Congress of the European Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top